Advertisement

Current Heart Failure Reports

, Volume 15, Issue 4, pp 201–213 | Cite as

Decompensated Heart Failure With Ventricular Arrhythmia: How Useful Is VT Ablation?

  • Gerasimos Dimitropoulos
  • Georgios Leventogiannis
  • Joseph De Bono
Decompensated Heart Failure (P Banerjee, Section Editor)
  • 25 Downloads
Part of the following topical collections:
  1. Topical Collection on Decompensated Heart Failure

Abstract

Purpose of Review

Ventricular arrhythmias are common in patients with heart failure. Their management especially in the context of decompensated heart failure poses a clinical challenge to modern cardiologists. In this review article, we aim to summarise the current evidence on the epidemiology, pathophysiology, and management of ventricular tachycardia in heart failure, focusing primarily on the use of catheter ablation.

Recent Findings

The evolution of electro-anatomical mapping techniques and ablation catheter technology in the recent years has paved the path for the successful application of catheter ablation in the treatment of ventricular arrhythmias. The efficacy of catheter ablation in the management of ventricular tachycardia in patients with chronic heart failure has recently been the epicentre of a number of randomised controlled trials, demonstrating promising results with regard to arrhythmia suppression and all-cause mortality. The usefulness of catheter ablation in decompensated heart failure has been explored to a lesser degree, primarily in the setting of an electrical storm.

Summary

Implantable cardiac defibrillators play the most important role in improving prognosis and preventing sudden cardiac death in patients with heart failure. Catheter ablation for the treatment of recurrent VT in patients with chronic heart failure is an efficacious strategy that can be applied adjunctively to or in instead of antiarrhythmic therapy, and it is highly successful at preventing recurrent ventricular tachycardia, ICD shocks. Its efficacy in the context of decompensated heart failure requires further research, with current evidence rendering its use promising.

Keywords

Ventricular tachycardia Catheter ablation Heart failure Electrical storm Structural heart disease Amiodarone 

Notes

Compliance with Ethical Standards

Conflict of Interest

Gerasimos Dimitropoulos declares no conflicts of interest.

Georgios Leventogiannis reports support from Biotronik.

Joseph De Bono reports support from Boston Scientific and Biosense.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. 1.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.  https://doi.org/10.1002/ejhf.592.CrossRefPubMedGoogle Scholar
  2. 2.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.  https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefPubMedGoogle Scholar
  3. 3.
    Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297–302.CrossRefPubMedGoogle Scholar
  4. 4.
    Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748–54.CrossRefPubMedGoogle Scholar
  5. 5.
    Raitt MH, Renfroe EG, Epstein AE, McAnulty JH, Mounsey P, Steinberg JS, et al. “Stable” ventricular tachycardia is not a benign rhythm : insights from the antiarrhythmics versus implantable defibrillators (AVID) registry. Circulation. 2001;103(2):244–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–17.  https://doi.org/10.1056/NEJMoa071098.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sweeney MO, Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7(3):353–60.  https://doi.org/10.1016/j.hrthm.2009.11.027.CrossRefPubMedGoogle Scholar
  8. 8.
    Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110(25):3760–5.  https://doi.org/10.1161/01.CIR.0000150390.04704.B7.CrossRefPubMedGoogle Scholar
  9. 9.
    Sacher F, Tedrow UB, Field ME, Raymond JM, Koplan BA, Epstein LM, et al. Ventricular tachycardia ablation: evolution of patients and procedures over 8 years. Circ Arrhythm Electrophysiol. 2008;1(3):153–61.  https://doi.org/10.1161/CIRCEP.108.769471.CrossRefPubMedGoogle Scholar
  10. 10.
    Lampert R, Wang Y, Curtis JP. Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: data from the National Cardiovascular Data Registry (NCDR) Implantable Cardioverter/Defibrillator (ICD) Registry. Am Heart J. 2013;165(6):1015–23 e2.  https://doi.org/10.1016/j.ahj.2012.12.003.CrossRefPubMedGoogle Scholar
  11. 11.
    Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017;2017:24390.Google Scholar
  12. 12.
    Cleland JG, Chattopadhyay S, Khand A, Houghton T, Kaye GC. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev. 2002;7(3):229–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998;98(15):1510–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Circulation. 1996;94(12):3198–203.CrossRefPubMedGoogle Scholar
  15. 15.
    Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.  https://doi.org/10.1056/NEJM199702203360801.CrossRefGoogle Scholar
  16. 16.
    Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, et al. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J. 2001;22(17):1601–12.  https://doi.org/10.1053/euhj.2000.2570.CrossRefPubMedGoogle Scholar
  17. 17.
    Liao YC, Hsieh YC, Hung CY, Huang JL, Lin CH, Wang KY, et al. Statin therapy reduces the risk of ventricular arrhythmias, sudden cardiac death, and mortality in heart failure patients: a nationwide population-based cohort study. Int J Cardiol. 2013;168(5):4805–7.  https://doi.org/10.1016/j.ijcard.2013.07.036.CrossRefPubMedGoogle Scholar
  18. 18.
    Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442–63.CrossRefPubMedGoogle Scholar
  19. 19.
    O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail. 2005;11(3):200–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–16.  https://doi.org/10.1016/j.ahj.2004.08.005.CrossRefPubMedGoogle Scholar
  21. 21.
    de Bakker JM, van Capelle FJ, Janse MJ, Wilde AA, Coronel R, Becker AE, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation. 1988;77(3):589–606.CrossRefPubMedGoogle Scholar
  22. 22.
    de Bakker JM, van Capelle FJ, Janse MJ, van Hemel NM, Hauer RN, Defauw JJ, et al. Macroreentry in the infarcted human heart: the mechanism of ventricular tachycardias with a “focal” activation pattern. J Am Coll Cardiol. 1991;18(4):1005–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Rajendran PS, Nakamura K, Ajijola OA, Vaseghi M, Armour JA, Ardell JL, et al. Myocardial infarction induces structural and functional remodelling of the intrinsic cardiac nervous system. J Physiol. 2016;594(2):321–41.  https://doi.org/10.1113/JP271165.CrossRefPubMedGoogle Scholar
  24. 24.
    Ajijola OA, Yagishita D, Reddy NK, Yamakawa K, Vaseghi M, Downs AM, et al. Remodeling of stellate ganglion neurons after spatially targeted myocardial infarction: neuropeptide and morphologic changes. Heart Rhythm. 2015;12(5):1027–35.  https://doi.org/10.1016/j.hrthm.2015.01.045.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Marrouche NF, Verma A, Wazni O, Schweikert R, Martin DO, Saliba W, et al. Mode of initiation and ablation of ventricular fibrillation storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2004;43(9):1715–20.  https://doi.org/10.1016/j.jacc.2004.03.004.CrossRefPubMedGoogle Scholar
  26. 26.
    Xing D, Martins JB. Triggered activity due to delayed afterdepolarizations in sites of focal origin of ischemic ventricular tachycardia. Am J Physiol Heart Circ Physiol. 2004;287(5):H2078–84.  https://doi.org/10.1152/ajpheart.00027.2004.CrossRefPubMedGoogle Scholar
  27. 27.
    Nakayama Y, Shimizu G, Hirota Y, Saito T, Kino M, Kitaura Y, et al. Functional and histopathologic correlation in patients with dilated cardiomyopathy: an integrated evaluation by multivariate analysis. J Am Coll Cardiol. 1987;10(1):186–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G, Epstein LM. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy: the importance of low-voltage scars. J Am Coll Cardiol. 2004;43(10):1834–42.  https://doi.org/10.1016/j.jacc.2004.01.029.CrossRefPubMedGoogle Scholar
  29. 29.
    Hsia HH, Callans DJ, Marchlinski FE. Characterization of endocardial electrophysiological substrate in patients with nonischemic cardiomyopathy and monomorphic ventricular tachycardia. Circulation. 2003;108(6):704–10.  https://doi.org/10.1161/01.CIR.0000083725.72693.EA.CrossRefPubMedGoogle Scholar
  30. 30.
    Bogun FM, Desjardins B, Good E, Gupta S, Crawford T, Oral H, et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53(13):1138–45.  https://doi.org/10.1016/j.jacc.2008.11.052.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108(1):54–9.  https://doi.org/10.1161/01.CIR.0000078641.19365.4C.CrossRefPubMedGoogle Scholar
  32. 32.
    Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48(10):1977–85.  https://doi.org/10.1016/j.jacc.2006.07.049.CrossRefPubMedGoogle Scholar
  33. 33.
    Delacretaz E, Stevenson WG, Ellison KE, Maisel WH, Friedman PL. Mapping and radiofrequency catheter ablation of the three types of sustained monomorphic ventricular tachycardia in nonischemic heart disease. J Cardiovasc Electrophysiol. 2000;11(1):11–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017;69(7):761–73.  https://doi.org/10.1016/j.jacc.2016.11.063.CrossRefPubMedGoogle Scholar
  35. 35.
    Furushima H, Chinushi M, Iijima K, Sanada A, Izumi D, Hosaka Y, et al. Ventricular tachyarrhythmia associated with hypertrophic cardiomyopathy: incidence, prognosis, and relation to type of hypertrophy. J Cardiovasc Electrophysiol. 2010;21(9):991–9.  https://doi.org/10.1111/j.1540-8167.2010.01769.x.CrossRefPubMedGoogle Scholar
  36. 36.
    Inada K, Seiler J, Roberts-Thomson KC, Steven D, Rosman J, John RM, et al. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011;22(1):41–8.  https://doi.org/10.1111/j.1540-8167.2010.01875.x.CrossRefPubMedGoogle Scholar
  37. 37.
    Sekhri V, Sanal S, Delorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;7(4):546–54.  https://doi.org/10.5114/aoms.2011.24118.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Furushima H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol. 2004;27(4):217–22.CrossRefPubMedGoogle Scholar
  39. 39.
    Dukkipati SR, Koruth JS, Choudry S, Miller MA, Whang W, Reddy VY. Catheter ablation of ventricular tachycardia in structural heart disease: indications, strategies, and outcomes—part II. J Am Coll Cardiol. 2017;70(23):2924–41.  https://doi.org/10.1016/j.jacc.2017.10.030.CrossRefPubMedGoogle Scholar
  40. 40.
    Ravens U. Mechano-electric feedback and arrhythmias. Prog Biophys Mol Biol. 2003;82(1–3):255–66.CrossRefPubMedGoogle Scholar
  41. 41.
    Zabel M, Koller BS, Sachs F, Franz MR. Stretch-induced voltage changes in the isolated beating heart: importance of the timing of stretch and implications for stretch-activated ion channels. Cardiovasc Res. 1996;32(1):120–30.CrossRefPubMedGoogle Scholar
  42. 42.
    Janse MJ, Coronel R, Wilms-Schopman FJ, de Groot JR. Mechanical effects on arrhythmogenesis: from pipette to patient. Prog Biophys Mol Biol. 2003;82(1–3):187–95.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen RL, Penny DJ, Greve G, Lab MJ. Stretch-induced regional mechanoelectric dispersion and arrhythmia in the right ventricle of anesthetized lambs. Am J Phys Heart Circ Phys. 2004;286(3):H1008–H14.Google Scholar
  44. 44.
    Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual β-adrenergic responsiveness. Circ Res. 2001;88(11):1159–67.CrossRefPubMedGoogle Scholar
  45. 45.
    Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res. 2004;61(2):208–17.CrossRefPubMedGoogle Scholar
  46. 46.
    Nuss HB, Kaab S, Kass DA, Tomaselli GF, Marban E. Cellular basis of ventricular arrhythmias and abnormal automaticity in heart failure. Am J Phys. 1999;277(1 Pt 2):H80–91.Google Scholar
  47. 47.
    Mebazaa A, Gheorghiade M, Zannad F, Parrillo JE. Acute heart failure. Springer Science & Business Media; 2009.Google Scholar
  48. 48.
    Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail. 2015;17(9):848–74.  https://doi.org/10.1002/ejhf.338.CrossRefPubMedGoogle Scholar
  49. 49.
    Poole-Wilson PA. The Cardiac Insufficiency Bisoprolol Study II. Lancet. 1999;353(9161):1360–1.  https://doi.org/10.1016/S0140-6736(05)74354-3.CrossRefPubMedGoogle Scholar
  50. 50.
    Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.CrossRefPubMedGoogle Scholar
  51. 51.
    Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333(2):77–82.  https://doi.org/10.1056/NEJM199507133330201. CrossRefPubMedGoogle Scholar
  52. 52.
    Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.  https://doi.org/10.1056/NEJMoa043399.CrossRefPubMedGoogle Scholar
  53. 53.
    Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30(10):1245–53.  https://doi.org/10.1093/eurheartj/ehp100.CrossRefPubMedGoogle Scholar
  54. 54.
    Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol. 2006;97(10A):13F–25F.  https://doi.org/10.1016/j.amjcard.2006.03.005.CrossRefPubMedGoogle Scholar
  55. 55.
    Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J. 2014;35(34):2295–302.  https://doi.org/10.1093/eurheartj/ehu164.CrossRefPubMedGoogle Scholar
  56. 56.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.  https://doi.org/10.1056/NEJMoa030207.CrossRefPubMedGoogle Scholar
  57. 57.
    Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340(24):1855–62.  https://doi.org/10.1056/NEJM199906173402402.CrossRefPubMedGoogle Scholar
  58. 58.
    Kuhlkamp V, Mewis C, Mermi J, Bosch RF, Seipel L. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol. 1999;33(1):46–52.CrossRefPubMedGoogle Scholar
  59. 59.
    Seidl K, Hauer B, Schwick NG, Zahn R, Senges J. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am J Cardiol. 1998;82(6):744–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165–71.  https://doi.org/10.1001/jama.295.2.165. CrossRefPubMedGoogle Scholar
  61. 61.
    Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006;114(2):104–9.  https://doi.org/10.1161/CIRCULATIONAHA.106.618421.CrossRefPubMedGoogle Scholar
  62. 62.
    Antiarrhythmics versus Implantable Defibrillators I. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–83.  https://doi.org/10.1056/NEJM199711273372202.CrossRefGoogle Scholar
  63. 63.
    Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg Canadian Implantable Defibrillator Study. Eur Heart J 2000;21(24):2071–8. doi: https://doi.org/10.1053/euhj.2000.2476.
  64. 64.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40.  https://doi.org/10.1056/NEJM199612263352601.CrossRefPubMedGoogle Scholar
  65. 65.
    Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.  https://doi.org/10.1056/NEJMoa013474.CrossRefPubMedGoogle Scholar
  66. 66.
    Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.  https://doi.org/10.1056/NEJMoa033088.CrossRefPubMedGoogle Scholar
  67. 67.
    Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.  https://doi.org/10.1056/NEJMoa032423.CrossRefPubMedGoogle Scholar
  68. 68.
    Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–30.  https://doi.org/10.1056/NEJMoa1608029.CrossRefPubMedGoogle Scholar
  69. 69.
    •• Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135(22):2106–15.  https://doi.org/10.1161/CIRCULATIONAHA.116.026910. First study to document relationship between late gadolinium enhancement on CMR and risk for SCD. CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Ziv O, Dizon J, Thosani A, Naka Y, Magnano AR, Garan H. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol. 2005;45(9):1428–34.  https://doi.org/10.1016/j.jacc.2005.01.035.CrossRefPubMedGoogle Scholar
  71. 71.
    Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation. 2000;101(11):1288–96.CrossRefPubMedGoogle Scholar
  72. 72.
    Volkmer M, Ouyang F, Deger F, Ernst S, Goya M, Bansch D, et al. Substrate mapping vs. tachycardia mapping using CARTO in patients with coronary artery disease and ventricular tachycardia: impact on outcome of catheter ablation. Europace. 2006;8(11):968–76.  https://doi.org/10.1093/europace/eul109.CrossRefPubMedGoogle Scholar
  73. 73.
    Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357(26):2657–65.  https://doi.org/10.1056/NEJMoa065457.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375(9708):31–40.  https://doi.org/10.1016/S0140-6736(09)61755-4.CrossRefPubMedGoogle Scholar
  75. 75.
    Kuck KH, Tilz RR, Deneke T, Hoffmann BA, Ventura R, Hansen PS et al. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the Multicenter Randomized Controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol. 2017;10(3). doi: https://doi.org/10.1161/CIRCEP.116.004422.
  76. 76.
    • Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–21.  https://doi.org/10.1056/NEJMoa1513614. First RCT comparing catheter ablation versus controlled escalated antiarrhythmic therapy for the treatment of VT. CrossRefPubMedGoogle Scholar
  77. 77.
    Santangeli P, Muser D, Maeda S, Filtz A, Zado ES, Frankel DS, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13(7):1552–9.  https://doi.org/10.1016/j.hrthm.2016.03.004.CrossRefPubMedGoogle Scholar
  78. 78.
    Tanner H, Hindricks G, Volkmer M, Furniss S, Kuhlkamp V, Lacroix D, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. 2010;21(1):47–53.  https://doi.org/10.1111/j.1540-8167.2009.01563.x.CrossRefPubMedGoogle Scholar
  79. 79.
    Marchlinski FE, Haffajee CI, Beshai JF, Dickfeld TL, Gonzalez MD, Hsia HH, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016;67(6):674–83.  https://doi.org/10.1016/j.jacc.2015.11.041.CrossRefPubMedGoogle Scholar
  80. 80.
    Tung R, Vaseghi M, Frankel DS, Vergara P, Di Biase L, Nagashima K, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an international VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12(9):1997–2007.  https://doi.org/10.1016/j.hrthm.2015.05.036.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Di Biase L, Burkhardt JD, Lakkireddy D, Carbucicchio C, Mohanty S, Mohanty P, et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy: the VISTA randomized multicenter trial. J Am Coll Cardiol. 2015;66(25):2872–82.  https://doi.org/10.1016/j.jacc.2015.10.026.CrossRefPubMedGoogle Scholar
  82. 82.
    Muser D, Santangeli P, Castro SA, Pathak RK, Liang JJ, Hayashi T et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9(10). doi: https://doi.org/10.1161/CIRCEP.116.004328.
  83. 83.
    Dinov B, Arya A, Schratter A, Schirripa V, Fiedler L, Sommer P, et al. Catheter ablation of ventricular tachycardia and mortality in patients with nonischemic dilated cardiomyopathy: can noninducibility after ablation be a predictor for reduced mortality? Circ Arrhythm Electrophysiol. 2015;8(3):598–605.  https://doi.org/10.1161/CIRCEP.114.002295.CrossRefPubMedGoogle Scholar
  84. 84.
    Dinov B, Fiedler L, Schonbauer R, Bollmann A, Rolf S, Piorkowski C, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129(7):728–36.  https://doi.org/10.1161/CIRCULATIONAHA.113.003063.CrossRefPubMedGoogle Scholar
  85. 85.
    Nakahara S, Tung R, Ramirez RJ, Michowitz Y, Vaseghi M, Buch E, et al. Characterization of the arrhythmogenic substrate in ischemic and nonischemic cardiomyopathy implications for catheter ablation of hemodynamically unstable ventricular tachycardia. J Am Coll Cardiol. 2010;55(21):2355–65.  https://doi.org/10.1016/j.jacc.2010.01.041.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    •• Ghanbari H, Baser K, Yokokawa M, Stevenson W, Della Bella P, Vergara P, et al. Noninducibility in postinfarction ventricular tachycardia as an end point for ventricular tachycardia ablation and its effects on outcomes: a meta-analysis. Circ Arrhythm Electrophysiol. 2014;7(4):677–83.  https://doi.org/10.1161/CIRCEP.113.001404. Meta-analysis demonstrating association between successful catheter ablation for VT and reduced mortality. CrossRefPubMedGoogle Scholar
  87. 87.
    Yokokawa M, Kim HM, Baser K, Stevenson W, Nagashima K, Della Bella P, et al. Predictive value of programmed ventricular stimulation after catheter ablation of post-infarction ventricular tachycardia. J Am Coll Cardiol. 2015;65(18):1954–9.  https://doi.org/10.1016/j.jacc.2015.02.058.CrossRefPubMedGoogle Scholar
  88. 88.
    Santangeli P, Frankel DS, Tung R, Vaseghi M, Sauer WH, Tzou WS, et al. Early mortality after catheter ablation of ventricular tachycardia in patients with structural heart disease. J Am Coll Cardiol. 2017;69(17):2105–15.  https://doi.org/10.1016/j.jacc.2017.02.044.CrossRefPubMedGoogle Scholar
  89. 89.
    •• Hayashi M, Miyauchi Y, Murata H, Takahashi K, Tsuboi I, Uetake S, et al. Urgent catheter ablation for sustained ventricular tachyarrhythmias in patients with acute heart failure decompensation. Europace. 2014;16(1):92–100.  https://doi.org/10.1093/europace/eut207. First trial to evaluate catheter ablation in acute decompensated HF. CrossRefPubMedGoogle Scholar
  90. 90.
    Chalvidan T, Deharo JC, Dieuzaide P, Defaye P, Djiane P. Near fatal electrical storm in a patient equipped with an implantable cardioverter defibrillator for Brugada syndrome. Pacing Clin Electrophysiol. 2000;23(3):410–2.CrossRefPubMedGoogle Scholar
  91. 91.
    Wilson CM, Allen JD, Bridges JB, Adgey AA. Death and damage caused by multiple direct current shocks: studies in an animal model. Eur Heart J. 1988;9(11):1257–65.CrossRefPubMedGoogle Scholar
  92. 92.
    Bansch D, Oyang F, Antz M, Arentz T, Weber R, Val-Mejias JE, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation. 2003;108(24):3011–6.  https://doi.org/10.1161/01.CIR.0000103701.30662.5C.CrossRefPubMedGoogle Scholar
  93. 93.
    Carbucicchio C, Santamaria M, Trevisi N, Maccabelli G, Giraldi F, Fassini G, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation. 2008;117(4):462–9.  https://doi.org/10.1161/CIRCULATIONAHA.106.686534.CrossRefPubMedGoogle Scholar
  94. 94.
    Deneke T, Shin DI, Lawo T, Bosche L, Balta O, Anders H, et al. Catheter ablation of electrical storm in a collaborative hospital network. Am J Cardiol. 2011;108(2):233–9.  https://doi.org/10.1016/j.amjcard.2011.03.030.CrossRefPubMedGoogle Scholar
  95. 95.
    Kozeluhova M, Peichl P, Cihak R, Wichterle D, Vancura V, Bytesnik J, et al. Catheter ablation of electrical storm in patients with structural heart disease. Europace. 2011;13(1):109–13.  https://doi.org/10.1093/europace/euq364.CrossRefPubMedGoogle Scholar
  96. 96.
    Izquierdo M, Ruiz-Granell R, Ferrero A, Martinez A, Sanchez-Gomez J, Bonanad C, et al. Ablation or conservative management of electrical storm due to monomorphic ventricular tachycardia: differences in outcome. Europace. 2012;14(12):1734–9.  https://doi.org/10.1093/europace/eus186.CrossRefPubMedGoogle Scholar
  97. 97.
    Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014;11(10):e166–96.  https://doi.org/10.1016/j.hrthm.2014.07.024.CrossRefPubMedGoogle Scholar
  98. 98.
    Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867.  https://doi.org/10.1093/eurheartj/ehv316.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Gerasimos Dimitropoulos
    • 1
  • Georgios Leventogiannis
    • 1
  • Joseph De Bono
    • 1
  1. 1.Cardiology DepartmentUniversity Hospital BirminghamBirminghamUK

Personalised recommendations